Updated from 4:01 p.m. EST
A Justice Department investigation into
Merck & Co.'s
marketing and selling activities continues, but there's no new developments in the case, the drugmaker said.
Merck disclosed in its 10-Q filed with the
Securities and Exchange Commission
that the probe was ongoing, and said it was working with the government to respond to requests for information. A spokesman subsequently said the investigation was the same one the company reported in March.
The clarification came after the market closed and Merck's shares ended down 3.7% to $52.80.
disclosed in its 10-Q filing that it received two subpoenas from the U.S. Attorney in Boston related to a previously disclosed investigation into sales and marketing activities of several drugs.
Schering-Plough ended down 4% to $20.66.